Manages OA 1.2 Rheumatoid Arthritis (RA). ANDA 205129, held by Sciegen Pharms. Celecoxib.
As of Nov 15, 2026, ANDA 205129 (Celecoxib), held by Sciegen Pharms, was first approved by FDA on Dec 3, 2020, with 3 approved supplements and 0 published complete response letters.
1. INDICATIONS AND USAGE Celecoxib capsules are indicated Celecoxib capsules are nonsteroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) Rheumatoid Arthritis (RA) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older Ankylosing Spondylitis (AS) Acute Pain (AP) Primary Dysmenorrhea (PD) 1.1 Osteoarthritis(OA) For the management of the signs and symptoms of OA 1.2 Rheumatoid Arthritis (RA) For the management of the signs and symptoms of RA 1.3 Juvenile Rheumatoid Arthritis (JRA) For the management of the signs and symptoms of JRA in patients 2 years and older 1.4 Ankylosing Spondylitis (AS) For the management of the signs and symptoms of AS 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 3, 2020 | Original application | Approved | None posted |
| Feb 26, 2025 | Supplement 14Labeling · Standard review | Approved | None posted |
| Feb 26, 2025 | Supplement 12Labeling · Standard review | Approved | None posted |
| Feb 28, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 3, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters